|
gptkbp:instance_of
|
gptkb:Clinical_Trials
|
|
gptkbp:advocacy
|
required from participants
|
|
gptkbp:analysis
|
statistical analysis
|
|
gptkbp:business_model
|
obtained
|
|
gptkbp:case_analysis
|
clinical events
|
|
gptkbp:clinical_trial
|
Phase III
NCT01032629
|
|
gptkbp:collaboration
|
academic-industry partnership
|
|
gptkbp:collaborator
|
gptkb:University_of_Oxford
|
|
gptkbp:collection
|
clinical assessments
during treatment and follow-up
|
|
gptkbp:committee
|
established
|
|
gptkbp:comparison_group
|
placebo group
|
|
gptkbp:events
|
scheduled visits
median of 4 years
|
|
gptkbp:focuses_on
|
treatment of diabetes
|
|
gptkbp:funding
|
public and private funding
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ASCEND trial
|
|
gptkbp:impact
|
influences diabetes treatment guidelines
|
|
gptkbp:intervention_type
|
pharmacological
|
|
gptkbp:investigates
|
Professor John Mc Murray
|
|
gptkbp:is_located_in
|
gptkb:Europe
gptkb:Asia
gptkb:Australia
gptkb:North_America
|
|
gptkbp:is_studied_in
|
randomized controlled trial
|
|
gptkbp:is_tested_for
|
Phase III
|
|
gptkbp:location
|
multiple countries
|
|
gptkbp:notable_work
|
support use of Dapagliflozin in diabetes management
|
|
gptkbp:outcome_measure_time_frame
|
3 years
|
|
gptkbp:participants
|
cardiovascular events
diabetes-related complications
|
|
gptkbp:patient_eligibility_criteria
|
age 40 and older
at least one cardiovascular risk factor
diagnosed with type 2 diabetes
|
|
gptkbp:prevention
|
gptkb:pharmaceuticals
|
|
gptkbp:primary_use
|
treatment
|
|
gptkbp:provides_information_on
|
available upon request
|
|
gptkbp:publication
|
peer-reviewed article
|
|
gptkbp:recruitment
|
ongoing until target met
|
|
gptkbp:related_products
|
gptkb:Dapagliflozin
|
|
gptkbp:research_output
|
published in The Lancet
|
|
gptkbp:result
|
gptkb:2021
indicate significant benefits
showed reduction in cardiovascular events
|
|
gptkbp:risk_factor
|
hypertension
cholesterol levels
body mass index
smoking status
|
|
gptkbp:safety_measures
|
ongoing throughout study
|
|
gptkbp:side_effect
|
monitored
|
|
gptkbp:sponsored_by
|
gptkb:Astra_Zeneca
|
|
gptkbp:start_date
|
gptkb:2015
|
|
gptkbp:student_enrollment
|
over 15,000 participants
|
|
gptkbp:study_design_type
|
multicenter study
|
|
gptkbp:study_status
|
completed
|
|
gptkbp:target_audience
|
patients with type 2 diabetes
|
|
gptkbp:year
|
gptkb:2020
|
|
gptkbp:bfsParent
|
gptkb:Pirfenidone
|
|
gptkbp:bfsLayer
|
8
|